[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484189":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":72,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL",null,[13],"Biological: ZGGS18 for Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","Tumor type: colorectal cancer，pancreatic cancer",[13],[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"BIOLOGICAL","ZGGS18 for Injection","0.3 mg\u002Fkg, 1 mg\u002Fkg, 3 mg\u002Fkg, 6 mg\u002Fkg, 10 mg\u002Fkg, 15 mg\u002Fkg and 20 mg\u002Fkgof ZGGS18，intravenous infusion, once every 2 weeks.",[9],{"type":20,"name":21,"description":25,"armGroupLabels":26,"otherNames":11},"Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.",[15],[28],{"name":29,"affiliation":5,"role":30},"Jason Wu","STUDY_DIRECTOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Shangdi Ning","CONTACT","+86-0512-57018308","ningsd@zelgen.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Chinese PLA General Hospital","RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":11,"phoneExt":11,"email":55},"Jianming Xu","Jianmingxu2014@163.com",{"type":57,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100484189","phase-1-study-of-zggs18-in-patients-with-advanced-solid-tumors-100484189",false,"NCT05584800","Study of ZGGS18 in Patients With Advanced Solid Tumors","A Phase I\u002FII Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of advanced solid tumors, who had failed the available standard treatments or no standard treatment or intolerance to standard treatment;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;\n* Life expectancy ≥ 3 months;\n* Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors 1.1(RECIST1.1). For lesions that have received radiation therapy, only after the progression of the lesions, they can be considered measurable lesions.\n\nExclusion Criteria:\n\n* The investigator considers that any subjects are not suitable to participate in the trial.","ALL","18 Years","75 Years",{"count":69,"type":70},222,"ESTIMATED","INTERVENTIONAL",[73,74],"PHASE1","PHASE2","A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors",[77],"Advanced Solid Tumor","2025-12-30",{"date":80,"type":81},"2026-01-05","ACTUAL",{"date":83,"type":81},"2022-11-15",{"date":85,"type":70},"2026-11-01",{"name":5,"class":6},1]